Journal of Mahatma Gandhi University of Medical Sciences and Technology

Register      Login

VOLUME 2 , ISSUE 2 ( 2017 ) > List of Articles

RESEARCH ARTICLE

Role of Lipid Profile in the Assessment of Nonalcoholic Steatohepatitis in Prediabetic and Diabetic Patients with Nonalcoholic Fatty Liver Disease

Bushra Fiza, Maheep Sinha, Lokesh Jain, Rajeev Kasliwal

Keywords : Insulin resistance, Lipid profile, Nonalcoholic fatty liver disease, Nonalcoholic steatohepatitis,Dyslipidemia

Citation Information : Fiza B, Sinha M, Jain L, Kasliwal R. Role of Lipid Profile in the Assessment of Nonalcoholic Steatohepatitis in Prediabetic and Diabetic Patients with Nonalcoholic Fatty Liver Disease. J Mahatma Gandhi Univ Med Sci Tech 2017; 2 (2):81-84.

DOI: 10.5005/jp-journals-10057-0041

License: CC BY-NC-ND 3.0

Published Online: 00-08-2017

Copyright Statement:  Copyright © 2017; Jaypee Brothers Medical Publishers (P) Ltd.


Abstract

Nonalcoholic fatty liver disease (NAFLD) is a chronic condition ranging from simple steatosis and fatty liver to more severe manifestations like nonalcoholic steatohepatitis (NASH), cirrhosis, and hepatocellular carcinoma. Excess fat deposition is common in NAFLD and it is strongly correlated with insulin resistance and associated conditions, such as obesity, metabolic syndrome, type II diabetes mellitus, or hyperglycemic conditions. Most people with NAFLD remain asymptomatic until development of irrever­sible damage of liver tissue. The present study was planned to study the role of lipid profile in assessment of NASH in prediabetic and diabetic patients with NAFLD. Prediabetic (n = 100) and diabetic (n = 100) patients with NAFLD were enrolled for the study. Of the total 200 patients, 16% confirmed for NASH. Serum cholesterol > 200 mg/dL, triglycerides > 150 mg/dL, and high-density lipoprotein (HDL) < 60 mg/dL exhibited a strong association with occurrence of NASH. The study demonstrated that increased cholesterol (p = 0.000) and triglyceride (p = 0.009) and low HDL (p = 0.006) were significant markers in NASH patients. The study therefore recommends that prediabetic and diabetic patients with NAFLD should be regularly screened for lipid levels and patients with dyslipidemia should be considered to be at risk of developing NASH. Early identification of the disease can be helpful in providing timely treatment. How to cite this article Kumar A, Fiza B, Jain L, Kasliwal R, Sinha M. Role of Lipid Profile in the Assessment of Nonalcoholic Steatohepatitis in Prediabetic and Diabetic Patients with Nonalcoholic Fatty Liver Disease. J Mahatma Gandhi Univ Med Sci Tech 2017;2(2):81-84.


PDF Share
  1. Ludwig J, Viggiano TR, McGill DB, Oh BJ. Nonalcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease. Mayo Clin Proc 1980 Jul;55(7):434-438.
  2. Fracanzani AL, Valenti L, Bugianesi E, Andreoletti M, Colli A, Vanni E, Bertelli C, Fatta E, Bignamini D, Marchesini G, et al. Risk of severe liver disease in nonalcoholic fatty liver disease with normal aminotransferase levels: a role for insulin resistance and diabetes. Hepatology 2008 Sep;48(3):792-798.
  3. Dai W, Ye L, Liu A, Wen SW, Deng J, Wu X, Lai Z. Prevalence of nonalcoholic fatty liver disease in patients with type 2 diabetes mellitus: a meta-analysis. Medicine (Baltimore) 2017 Sep;96(39):e8179.
  4. Spengler EK, Loomba R. Recommendations for diagnosis, referral for liver biopsy, and treatment of NAFLD and NASH. Mayo Clin Proc 2015 Sep;90(9):1233-1246.
  5. Okanoue T, Ohta M, Ou O, Kachi K, Kagawa K, Yuki T, Okuno T, Takino T, French SW. Relationship of Mallory bodies to intermediate filaments in hepatocytes. A scanning electron microscopy study. Lab Invest 1985 Nov;53(5):534-540.
  6. El-Serag HB, Tran T, Everhart JE. Diabetes increases the risk of chronic liver disease and hepatocellular carcinoma. Gastroenterology 2004 Feb;126(2):460-468.
  7. Portillo P, Yavuz S, Bril F, Cusi K. Role of insulin resistance and diabetes in the pathogenesis and treatment of nonalcoholic fatty liver disease. Curr Hepatol Rep 2014,13:159-170.
  8. Cusi K. Role of obesity and lipotoxicity in the development of nonalcoholic steatohepatitis: pathophysiology and clinical implications. Gastroenterology 2012 Apr;142(4):711.e6-725.e6.
  9. Wong VW, Chu WC, Wong GL, Chan RS, Chim AM, Ong A, Yeung DK, Yiu KK, Chu SH, Woo J, et al. Prevalence of nonalcoholic fatty liver disease and advanced fibrosis in Hong Kong Chinese: a population study using proton-magnetic resonance spectroscopy and transient elastography. Gut 2012 Mar;61(3):409-415.
  10. Souza MR, Diniz Mde F, Medeiros-Filho JE, Araujo MS. Metabolic syndrome and risk factors for non-alcoholic fatty liver disease. Arq Gastroenterol 2012 Jan-Mar;49(1):89-96.
  11. Bugianesi E, Gastaldelli A, Vanni E, Gambino R, Cassader M, Baldi S, Ponti V, Pagano G, Ferrannini E, Rizzetto M. Insulin resistance in non-diabetic patients with non-alcoholic fatty liver disease: sites and mechanisms. Diabetologia 2005 Apr;48(4):634-642.
  12. Fabbrini E, Mohammed BS, Magkos F, Korenblat KM, Patterson BW, Klein S. Alterations in adipose tissue and hepatic lipid kinetics in obese men and women with nonalcoholic fatty liver disease. Gastroenterology 2008 Feb;134(2):424-431.
  13. Adiels M, Taskinen MR, Packard C, Caslake MJ, Soro-Paavonen A, Westerbacka J, Vehkavaara S, Häkkinen A, Olofsson SO, Yki-Järvinen H, et al. Overproduction of large VLDL particles is driven by increased liver fat content in man. Diabetologia 2006 Apr;49(4):755-765.
  14. Targher G, Bertolini L, Padovani R, Rodella S, Tessari R, Zenari L, Day C, Arcaro G. Prevalence of nonalcoholic fatty liver disease and its association with cardiovascular disease among type 2 diabetic patients. Diabetes Care 2007 May;30(5):1212-1218.
  15. Barrows BR, Timlin MT, Parks EJ. Spillover of dietary fatty acids and use of serum nonesterified fatty acids for the synthesis of VLDL-triacylglycerol under two different feeding regimens. Diabetes 2005 Sep;54(9):2668-2673.
  16. Chapman MJ, Ginsberg HN, Amarenco P, Andreotti F, Boren J, Catapano AL, Descamps OS, Fisher E, Kovanen PT, Kuivenhoven JA, et al. Triglyceride-rich lipoproteins and high-density lipoprotein cholesterol in patients at high risk of cardiovascular disease: evidence and guidance for management. Eur Heart J 2011 Jun;32(11):1345-1361.
  17. Kantartzis K, Rittig K, Cegan A, Machann J, Schick F, Balletshofer B, Fritsche A, Schleicher E, Haring HU, Stefan N. Fatty liver is independently associated with alterations in circulating HDL2 and HDL3 subfractions. Diabetes Care 2008 Feb;31(2):366-368.
  18. Gastaldelli A. Fatty liver disease: the hepatic manifestation of metabolic syndrome. Hypertens Res 2010 Jun;33(6):546-547.
  19. Vanni E, Bugianesi E, Kotronen A, De Minicis S, Yki-Jarvinen H, Svegliati-Baroni G. From the metabolic syndrome to NAFLD or vice versa? Dig Liver Dis 2010 May;42(5):320-330.
  20. Sampogna F, Raskovic D, Guerra L, Pedicelli C, Tabolli S, Leoni L, Alessandroni L, Abeni D. Identification of categories at risk for high quality of life impairment in patients with vitiligo. Br J Dermatol 2008 Aug;159(2):351-359.
  21. Ramakrishna P, Rajni T. Psychiatric morbidity and quality of life in vitiligo patients. Indian J Psychol Med 2015 Jan-Mar;37(1):111.
  22. Ue AP, Souza PK, Rotta O, Furlani Wde J, Lima AR, Sabbag DS. Quality of life assessment in patients with chronic urticaria. An Bras Dermatol 2011 Sep-Oct;86(5):897-904.
  23. Ben-Shoshan M, Blinderman I, Raz A. Psychosocial factors and chronic spontaneous urticaria: a systematic review. Eur J Allergy Clin Immunol 2013 Feb;68(2):131-141.
  24. Sawant N, Chikhalkar S, Mehta V, Ravi M, Madke B, Khopkar U. Androgenetic alopecia: quality-of-life and associated lifestyle patterns. Int J Trichol 2010 Jul;2(2):81-85.
  25. Cash TF, Price VH, Savin RC. Psychological effects of androgenetic alopecia on women: comparisons with balding men and with female control subjects. J Am Acad Dermatol 1993 Oct;29(4):568-575.
  26. Van Der Donk J, Hunfeld JA, Passchier J, Knegt-Junk KJ, Nieboer C. Quality of life and maladjustment associated with hair loss in women with alopecia androgenetica. Soc Sci Med 1994 Jan;38(1):159-163.
  27. Van Passchier J, Dutree-Meulenberg RO, Stolz E, Verhage F. Psychological characteristics of men with alopecia androgenetica and their modification. Int J Dermatol 1991 Jan;30(1):22-28.
  28. Garg G, Singh S. Intramedullary spinal tuberculoma. Br J Neurosurg 2002;16:75-76.
  29. Rao GP. Spinal intramedullary tuberculous lesion: medical management. Report of four cases. J Neurosurg 2000;93(Suppl 1):137-141.
  30. Jena A, Banerji AK, Tripathi RP, Gulati PK, Jain RK, Khushu S, Sapra ML. Demonstration of intramedullary tuberculomas by magnetic resonance imaging: a report of two cases. Br J Radiol 1991;64(762):555-558.
  31. Citow JS, Ammirati M. Intramedullary tuberculoma of the spinal cord: case report. Neurosurgery 1994 Aug;35(2):327-330.
  32. Medhi S, Goswami B, Das AK, Singh TB, Husain SA, Sehgal A, Kar P. New insights into hepatitis C virus infection in the tribal-dominant part of Northeast India. Arch Virol 2012 Nov;157(11):2083-2093.
  33. Raghuraman S, Abraham P, Sridharan G, Ramakrishna BS. Hepatitis C virus genotype 6 infection in India. Indian. J Gastroenterol 2005 Mar-Apr;24(2):72-75.
  34. Raghuraman S, Abraham P, Sridharan G, Daniel HD, Ramakrishna BS, Shaji RV. HCV genotype 4 — an emerging threat as a cause of chronic liver disease in Indian (south) patients. J Clin Virol 2004 Dec;31(4):253-258.
  35. Umer M, Iqbal M. Hepatitis C virus prevalence and genotype distribution in Pakistan: comprehensive review of recent data. World J Gastroenterol 2016 Jan;22(4):1684-1700.
  36. Esmaeilzadeh A, Erfanmanesh M, Ghasemi S, Mohammadi F. Serological assay and genotyping of hepatitis C virus in infected patients in Zanjan province. Hepat Mon 2014 Sep;14(9):e17323.
  37. Mittal G, Gupta P, Gupta R, Ahuja V, Mittal M, Dhar M. Seroprevalence and risk factors of hepatitis B and hepatitis C virus infections in Uttarakhand, India. J Clin Exp Hepatol 2013 Dec;3(4):296-300.
  38. Sarma MP, Asim M, Medhi S, Bharathi T, Diwan R, Kar P. Viral genotypes and associated risk factors of hepatocellular carcinoma in India. Cancer Bio Med 2012 Sep;9(3):172-181.
  39. Ullah, Mi Hasan, F Najmudin, Alam, MM SSZZ, Rana, MS Nawaz, M Rehman S and Shah A A. Seroprevalence of Hepatitis C Virus Infection in Kohat Division, Khyber Pakhtoonkhwa, Pakistan. Pakistan J Zool 2016;.48(6):1721-1725.
  40. Ramarokoto CE, Rakotomanana F, Ratsitorahina M, Raharimanga V, Razafindratsimandresy R, Randremanana R, Rakoto-Andrianarivelo M, Rousset D, Andrianaja V, Richard V, et al. Seroprevalence of hepatitis C and associated risk factors in urban areas of Antananarivo, Madagascar. BMC Infect Dis 2008 Feb;8:25.
  41. Singh P, Kaur R, Kaur A. Frequency distribution of Hepatitis C virus in different geographical regions of Punjab: retrospective study from a tertiary care centre in North India. J Nat Sci Biol Med 2014 Jan;5(1):56-58.
  42. Sandhu R, Dahiya S. Prevalence of anti-hepatitis C virus antibodies among inpatients and outdoor attendees of a tertiary care institute. Br Biomed Bull 2015 Jan;3(1):8-14.
  43. Da Ros CT, Schmitt CdaS. Global epidemiology of sexually transmitted diseases. Asian J Androl 2008 Jan;10(1): 110-114.
  44. Te HS, Jensen DM. Epidemiology of hepatitis B and C viruses: a global overview. Clin Liver Dis 2010 Feb;14(1):1-21.
  45. Khan IA, Pilli S A S, Rampal R, Chauhan SK, Tiwari V, Mouli VP, Kedia S, Nayak B, Das P, Makharia GK, et al. Prevalence and Association of Mycobacterium avium subspecies paratuberculosis with disease course in patients with ulcero-constrictive ileocolonic disease. PLoS One 2016 Mar;11(3):e0152063.
  46. Ramadass B, Chittaranjan S, Subramanian V, Ramakrishna BS. Fecal polymerase chain reaction for Mycobacterium tuberculosis IS6110 to distinguish Crohn's disease from intestinal tuberculosis. Indian J Gastroenterol 2010 Jul;29(4):152-156.
  47. Jin XJ, Kim JM, Kim HK, Kim L, Choi SJ, Park IS, Han JY, Chu YC, Song JY, Kwon KS, et al. Histopathology and TB-PCR kit analysis in differentiating the diagnosis of intestinal tuberculosis and Crohn's disease. World J Gastroenterol 2010 May;16(20):2496-2503.
  48. Jin T, Fei B, Zhang Y, He X. The diagnostic value of polymerase chain reaction for Mycobacterium tuberculosis to distinguish intestinal tuberculosis from Crohn's disease: a meta-analysis. Saudi J Gastroenterol 2017 Jan-Feb;23(1):3-10.
  49. Sechi LA, Mura M, Tanda F, Lissia A, Solinas A, Fadda G, Zanetti S. Identification of Mycobacterium avium subsp. paratuberculosis in biopsy specimens from patients with Crohn's disease identified by in situ hybridization. J Clin Microbiol 2001 Dec;39(12):4514-4517.
  50. Sechi LA, Mura M, Tanda E, Lissia A, Fadda G, Zanetti S. Mycobacterium avium sub. paratuberculosis in tissue samples of Crohn's disease patients. New Microbiol 2004 Jan;27(1):75-77.
  51. Sechi LA, Scanu AM, Molicotti P, Cannas S, Mura M, Dettori G, Fadda G, Zanetti S. Detection and Isolation of Mycobacterium avium subspecies paratuberculosis from intestinal mucosal biopsies of patients with and without Crohn's disease in Sardinia. Am J Gastroenterol 2005 Jul;100(7):1529-1536.
  52. Pulimood AB, Peter S, Rook GW, Donoghue HD. In situ PCR for Mycobacterium tuberculosis in endoscopic mucosal biopsy specimens of intestinal tuberculosis and Crohn disease. Am J Clin Pathol 2008 Jun;129(6):846-851.
  53. Aimaiti R, Qin L, Cao T, Yang H, Wang J, Lu J, Huang X, Hu Z. Identification and application of ssDNA aptamers against H37Rv in the detection of Mycobacterium tuberculosis. Appl Microbiol Biotechnol 2015 Nov;99(21):9073-9083.
  54. Mozioglu E, Gokmen O, Tamerler C, Kocagoz ZT, Akgoz M. Selection of nucleic acid aptamers specific for Mycobacterium tuberculosis. Appl Biochem Biotechnol 2016 Feb;178(4):849-864.
  55. Tang XL, Wu SM, Xie Y, Song N, Guan Q, Yuan C, Zhou X, Zhang XL. Generation and application of ssDNA aptamers against glycolipid antigen ManLAM of Mycobacterium tuberculosis for TB diagnosis. J Infect 2016 May;72(5):573-586.
  56. Pan Q, Wang Q, Sun X, Xia X, Wu S, Luo F, Zhang XL. Aptamer against mannose-capped lipoarabinomannan inhibits virulent Mycobacterium tuberculosis infection in mice and rhesus monkeys. Mol Ther 2014 May;22(5):940-951.
  57. Perkins AC, Missailidis S. Radiolabelled aptamers for tumour imaging and therapy. Q J Nucl Med Mol Imaging 2007 Dec;51(4):292-296.
  58. Calzada V, Moreno M, Newton J, González J, Fernández M, Gambini JP, Ibarra M, Chabalgoity A, Deutscher S, Quinn T, et al. Development of new PTK7-targeting aptamer-fluorescent and radiolabelled probes for evaluation as molecular imaging agents: lymphoma and melanoma in vivo proof of concept. Bioorg Med Chem 2016 Dec;25(3):1163-1171.
  59. Lele, RD. Imaging tuberculosis with radiolabelled aptamers. In: Kulkarni SV, editor. Pursuit of excellence—an autobiography. Mumbai: Granthali Woollen Mill Public School; 2017. pp. 154-156.
  60. Fogel R, Limson J. Developing biosensors in developing countries: South Africa as a case study. Biosensors (Basel) 2016 Feb;6(1):E5.
  61. Chen F, Zhou J, Luo F, Mohammed AB, Zhang XL. Aptamer from whole-bacterium SELEX as new therapeutic reagent against virulent Mycobacterium tuberculosis. Biochem Biophys Res Commun 2007 Jun;357(3):743-748.
  62. Baig IA, Moon JY, Lee SC, Ryoo SW, Yoon MY. Development of ssDNA aptamers as potent inhibitors of Mycobacterium tuberculosis acetohydroxy acid synthase. Biochim Biophys Acta 2015 Oct;1854(10 Pt A):1338-1350.
  63. Sohal JS, Sheoran N, Narayanasamy K, Brahmachari V, Singh S, Subodh S. Genomic analysis of local isolate of Mycobacterium avium subspecies paratuberculosis. Vet Microbiol 2009 Mar;134(3-4):375-382.
PDF Share

© Jaypee Brothers Medical Publishers (P) LTD.